High-Dose Testosterone and Radioligand Therapy for Prostate Cancer

This trial tests whether a high dose of testosterone (specifically testosterone cypionate) followed by targeted radioligand therapy (a type of radioactive treatment) can treat prostate cancer that has spread and resists standard hormone therapy. The study will last about six months, with participants taking the study drug for 3.5 months. It seeks men with prostate cancer that has progressed despite low testosterone levels, who haven't experienced severe cancer symptoms, and who have a positive PSMA PET scan (a specific type of imaging test). Participants should already be receiving androgen deprivation therapy (a treatment to lower testosterone) and have undergone some other treatments, such as certain chemotherapy drugs. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications, but there is a 4-week washout period required for any prior investigational agents before enrollment.

A previous study found high-dose testosterone therapy to be safe for men with advanced prostate cancer that no longer responds to standard hormone treatments. This study showed no increased risk of the cancer worsening or returning in men receiving testosterone therapy. Some men even had a lower risk of developing more aggressive cancer types.

For PSMA-617, a type of targeted radiation therapy, research has shown it to be generally well-tolerated. Many patients experienced only mild side effects. This treatment has been associated with positive outcomes, such as reduced pain and longer survival.

Most treatments for prostate cancer focus on reducing androgen levels or blocking androgen receptors. But this new approach using high-dose testosterone cypionate is different. Researchers are excited about it because, unlike traditional treatments, this method involves flooding the body with testosterone, which may make cancer cells more vulnerable to subsequent radioligand therapy with PSMA-617. This combination could potentially enhance the effectiveness of the standard androgen deprivation therapy, offering new hope for patients with advanced prostate cancer.

Research has shown that high doses of testosterone can make prostate cancer cells more responsive to hormone treatments again. This method shows promise, particularly for cancers that no longer respond to standard hormone treatments. Studies also indicate that testosterone therapy does not increase the risk of prostate cancer worsening.